Insulin analogues - State of the art

Hormone Research

Volumn 57, Issue SUPPL. 1, 2002, Pages 40-45

  Standl, Eberhard ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

Insulin aspart; Insulin detemir; Insulin glargine; Insulin lispro; Long term safety; Quality of life Hypoglycaemia; Weight control

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN;

BODY WEIGHT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; WEIGHT GAIN;

CHEMISTRY; DIABETES MELLITUS; ENDOCRINOLOGY; HUMANS; INSULIN; QUALITY OF LIFE; SELF CONCEPT;

EID: 0036234837     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053311     Document Type: Conference Paper

References (35)

1. The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus
2. Clinical efficacy and pharmacodynamics of the insulin analogs lispro, aspart and glargine
3. Time action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
4. Insulinanaloga: Results of a survey
5. Insulin analogues and their potential in the management of diabetes mellitus
6. Restauration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
7. Comparisons of insulin regimens for patients with type 2 diabetes
8. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients
9. Use of insulin aspart, a fast acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
10. Insulin aspart vs human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial
11. 1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps
12. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial
13. Insulin lispro in CSII: Results of a double- blind crossover study
14. 1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime
15. Use of the short- acting insulin analog lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal
16. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin
17. Longterm intensive treatment of type 1 diabetes with the short acting insulin analog lispro in variable combination with NPH insulin at mealtime
18. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin - Analog treatment
19. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
20. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type I diabetes
21. Insulin glargine
22. Efficacy and safety of Hoe 901 versus NPH insulin in patients with type 1 diabetes
23. Less hypoglycemia with insulin glargine in intensive therapy for type 1 diabetes
24. Basal insulin glargine (Hoe 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
25. A 16-week comparison of the novel insulin analog glargine (Hoe 901) and NPH insulin used with insulin lispro in patients with type 1 diabetes
26. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
27. Efficacy and safety of Hoe 901 (insulin glargine) in subjects with type 2 diabetes mellitus: A 28-week randomised, NPH-insulin controlled trial
28. Pharmacokinetic and pharmacodynamic properties of long acting analog NN304 in comparison to NPH insulin in humans
29. Comparison of the soluble basal insulin analog detemir with NPH insulin. A randomised open crossover trial in type1 diabetic subjects on basal- bolus therapy
30. Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal-bolus regimen
31. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed to clinical use
32. The long acting human insulin analog Hoe 901: Characteristics of insulin signalling in comparison to Asp (B10) and regular insulin
33. Safety of insulin lispro: Pooled data from clinical trials